Publications

Patient-Reported Health-Related Quality of Life from the Phase Iii Tourmaline-Mm1 Study of Ixazomib-Lenalidomide-Dexamethasone Versus Placebo-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

AuthID
P-00P-GKM

Author(s)

Leleu, X

Masszi, T

Bahlis, NJ

Viterbo, L

Baker, B

Gimsing, P

Maisnar, V

Samoilova, O

Rosinol, L

Langer, C

Song, K

Izumi, T

Cleeland, C

Berg, D

Lin, HM

Zhu, YY

Skacel, T

Moreau, P

Richardson, PG

Document Type

Article

Year published

2018

Published

in AMERICAN JOURNAL OF HEMATOLOGY, ISSN: 0361-8609

Volume: 93, Issue: 8, Pages: 985-993 (9)

Indexing

Wos^®

Scopus^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1002/ajh.25134

Scopus: 2-s2.0-85051706104

Wos: WOS:000441741100015

Source Identifiers

ISSN: 0361-8609

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Patient-Reported Health-Related Quality of Life from the Phase Iii Tourmaline-Mm1 Study of Ixazomib-Lenalidomide-Dexamethasone Versus Placebo-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

Useful Links

Get Help

Federated Authentication (Click on the image)

Patient-Reported Health-Related Quality of Life from the Phase Iii Tourmaline-Mm1 Study of Ixazomib-Lenalidomide-Dexamethasone Versus Placebo-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

Useful Links

Get Help